Preferences for Certainty Versus Access When Evaluating New Cancer Drugs. A Discrete Choice Experiment.
Preferences of Individuals in the United States With Personal Experience of Cancer for Certainty Versus Access When Evaluating New Cancer Drugs. A Discrete Choice Experiment.
1 other identifier
observational
998
1 country
1
Brief Summary
To provide timely access to new treatments, some eligible drugs can be approved despite uncertainty surrounding the level of clinical benefit they offer patients. It is not currently known if (and under which circumstances) people would prefer to wait to access some new drugs in exchange for greater certainty surrounding their clinical benefit. This study aims to elicit the preferences of people in the US with experience of cancer for wait times and clinical uncertainty of new drugs. To elicit this information, in a survey format, respondents will be presented with a hypothetical scenario and asked to state their preferences for new treatments, each with different attributes.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jul 2023
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
June 26, 2023
CompletedStudy Start
First participant enrolled
July 7, 2023
CompletedFirst Posted
Study publicly available on registry
July 10, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 20, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
July 20, 2023
CompletedJune 11, 2024
June 1, 2024
13 days
June 26, 2023
June 10, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Preferences for treatment attributes and trade-offs between attributes.
Preferences for different treatment attributes (including clinical uncertainty and wait time), and trade-offs between these, using a study-specific Discrete Choice Experiment (DCE) Questionnaire. Preferences are measured on relative utility scale (arbitrary units, no min/max). Utility indicates preference e.g., higher values are more preferred (better).
Through study completion, an average of 4-8 weeks.
Interventions
DCE survey experiment
Eligibility Criteria
Online survey panel consisting of a US nationally representative sample (age, gender, income, race/ethnicity, US state).
You may qualify if:
- Individuals previously or currently diagnosed with any type of cancer.
- Individuals with immediate family members previously or currently diagnosed with any type of cancer.
You may not qualify if:
- Individuals without previous or current diagnosis with any type of cancer (themselves or immediate family members).
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
London School of Economics
London, WC2A 2AE, United Kingdom
Related Publications (1)
Forrest R, Lagarde M, Aggarwal A, Naci H. Preferences for speed of access versus certainty of the survival benefit of new cancer drugs: a discrete choice experiment. Lancet Oncol. 2024 Dec;25(12):1635-1643. doi: 10.1016/S1470-2045(24)00596-5. Epub 2024 Nov 18.
PMID: 39571597DERIVED
MeSH Terms
Conditions
Study Design
- Study Type
- observational
- Observational Model
- OTHER
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principal Investigator
Study Record Dates
First Submitted
June 26, 2023
First Posted
July 10, 2023
Study Start
July 7, 2023
Primary Completion
July 20, 2023
Study Completion
July 20, 2023
Last Updated
June 11, 2024
Record last verified: 2024-06
Data Sharing
- IPD Sharing
- Will not share